Nasal Test Developed to Diagnose Creutzfeldt-Jakob Disease
By LabMedica International staff writers Posted on 19 Aug 2014 |
Image: The nasal brushing test involves the insertion of a rigid fiber-optic rhinoscope into the patient’s nasal cavity. A sterile brush is then inserted alongside the scope to collect olfactory neurons by gently rolling along the mucosal surface (Photo courtesy of Dr. Gianluigi Zanusso, MD, PhD).
A nasal brush test has been developed that can rapidly and accurately diagnose Creutzfeldt-Jakob disease (CJD), an incurable and ultimately fatal neurodegenerative disorder.
Definite diagnosis of sporadic CJD in living patients remains a challenge as up to now, a definitive CJD diagnosis requires testing brain tissue obtained after death or by biopsy in living patients.
An international team of scientists led by those at the National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) studied 31 nasal samples from patients with CJD and 43 nasal samples from patients who had other neurologic diseases or no neurologic disease at all. They obtained olfactory mucosa samples by using a nasal tampon, a rigid fiberoptic rhinoscope, enveloped with a disposable sheath, the Slide-On EndoSheath System (Medtronic Xomed; Minneapolis, MN, USA) and a sterile, disposable brush was then inserted alongside the fibroscope, gently rolled on the mucosal surface and withdrawn, and processed.
An in vitro PrPCJD amplification technology, designated real-time quaking-induced conversion (RT-QuIC), has been shown to have considerable promise as a highly specific diagnostic test for sporadic Creutzfeldt–Jakob disease. Testing with RT-QuIC correctly identified 30 of the 31 CJD patients (97% sensitivity) and correctly showed negative results for all 43 of the non-CJD patients (100% specificity). By comparison, tests using cerebral spinal fluid which is currently used to detect sporadic CJD were 77% sensitive and 100% specific, and the results took twice as long to obtain.
Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, said, “This exciting advance, the culmination of decades of studies on prion diseases, markedly improves on available diagnostic tests for CJD that are less reliable, more difficult for patients to tolerate, and require more time to obtain results. With additional validation, this test has potential for use in clinical and agricultural settings.” The study was published on August 7, 2014, in the New England Journal of Medicine (NEJM).
Related Links:
US National Institute of Allergy and Infectious Diseases
Medtronic Xomed
Definite diagnosis of sporadic CJD in living patients remains a challenge as up to now, a definitive CJD diagnosis requires testing brain tissue obtained after death or by biopsy in living patients.
An international team of scientists led by those at the National Institute of Allergy and Infectious Diseases (Bethesda, MD, USA) studied 31 nasal samples from patients with CJD and 43 nasal samples from patients who had other neurologic diseases or no neurologic disease at all. They obtained olfactory mucosa samples by using a nasal tampon, a rigid fiberoptic rhinoscope, enveloped with a disposable sheath, the Slide-On EndoSheath System (Medtronic Xomed; Minneapolis, MN, USA) and a sterile, disposable brush was then inserted alongside the fibroscope, gently rolled on the mucosal surface and withdrawn, and processed.
An in vitro PrPCJD amplification technology, designated real-time quaking-induced conversion (RT-QuIC), has been shown to have considerable promise as a highly specific diagnostic test for sporadic Creutzfeldt–Jakob disease. Testing with RT-QuIC correctly identified 30 of the 31 CJD patients (97% sensitivity) and correctly showed negative results for all 43 of the non-CJD patients (100% specificity). By comparison, tests using cerebral spinal fluid which is currently used to detect sporadic CJD were 77% sensitive and 100% specific, and the results took twice as long to obtain.
Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, said, “This exciting advance, the culmination of decades of studies on prion diseases, markedly improves on available diagnostic tests for CJD that are less reliable, more difficult for patients to tolerate, and require more time to obtain results. With additional validation, this test has potential for use in clinical and agricultural settings.” The study was published on August 7, 2014, in the New England Journal of Medicine (NEJM).
Related Links:
US National Institute of Allergy and Infectious Diseases
Medtronic Xomed
Latest Technology News
- New Diagnostic System Achieves PCR Testing Accuracy
- DNA Biosensor Enables Early Diagnosis of Cervical Cancer
- Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
- Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
- First of Its Kind Technology Detects Glucose in Human Saliva
- Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop
- Novel Noninvasive Test Detects Malaria Infection without Blood Sample
- Portable Optofluidic Sensing Devices Could Simultaneously Perform Variety of Medical Tests
- Point-of-Care Software Solution Helps Manage Disparate POCT Scenarios across Patient Testing Locations
- Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents
- Breakthrough Test Detects Biological Markers Related to Wider Variety of Cancers
- Rapid POC Sensing Kit to Determine Gut Health from Blood Serum and Stool Samples
- Device Converts Smartphone into Fluorescence Microscope for Just USD 50
- Wi-Fi Enabled Handheld Tube Reader Designed for Easy Portability